Angiogenesis Imaging Using Ga-68-RGD PET/CT: Therapeutic Implications
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Eo, Jae Seon | - |
dc.contributor.author | Jeong, Jae Min | - |
dc.date.accessioned | 2021-09-03T20:13:29Z | - |
dc.date.available | 2021-09-03T20:13:29Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 0001-2998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87572 | - |
dc.description.abstract | Angiogenesis imaging is important for diagnostic and therapeutic treatment of various malignant and nonmalignant diseases. The Arg-Gly-Asp (RGD) sequence has been known to bind with the alpha(v)beta(3) integrin that is expressed on the surface of angiogenic blood vessels or tumor cells. Thus, various radiolabeled derivatives of RGD peptides have been developed for angiogenesis imaging. Among the various radionuclides, Ga-68 was the most widely studied for RGD peptide imaging because of its excellent nuclear physical properties, easy-to-label chemical properties, and cost-effectiveness owing to the availability of a Ge-68-Ga-68 generator. Thus, various Ga-68-labeled RGD derivatives have been developed and applied for preclinical and clinical studies. Clinical trials were performed for both malignant and nonmalignant diseases. Breast cancer, glioma, and lung cancer were malignant, and myocardial infarction, atherosclerosis, and moyamoya disease were nonmalignant among the investigated diseases. Further, these Ga-68-labeled RGD derivatives could be applied to assess the effects of antiangiogenic treatment or theragnosis or both, of cancers. In conclusion, the angiogenesis imaging technology using Ga-68-labeled RGD derivatives might be useful for the development of new therapeutic assessments, and for diagnostic and theragnostic applications. (C) 2016 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | W B SAUNDERS CO-ELSEVIER INC | - |
dc.subject | ALPHA(V)BETA(3) INTEGRIN EXPRESSION | - |
dc.subject | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject | RGD PEPTIDES | - |
dc.subject | GA-68-NOTA-RGD PET | - |
dc.subject | FUSION PROTEIN | - |
dc.subject | RECEPTOR | - |
dc.subject | TRACERS | - |
dc.subject | CANCER | - |
dc.subject | TUMORS | - |
dc.subject | FEASIBILITY | - |
dc.title | Angiogenesis Imaging Using Ga-68-RGD PET/CT: Therapeutic Implications | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Eo, Jae Seon | - |
dc.identifier.doi | 10.1053/j.semnuclmed.2016.04.001 | - |
dc.identifier.scopusid | 2-s2.0-84983030811 | - |
dc.identifier.wosid | 000382423000006 | - |
dc.identifier.bibliographicCitation | SEMINARS IN NUCLEAR MEDICINE, v.46, no.5, pp.419 - 427 | - |
dc.relation.isPartOf | SEMINARS IN NUCLEAR MEDICINE | - |
dc.citation.title | SEMINARS IN NUCLEAR MEDICINE | - |
dc.citation.volume | 46 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 419 | - |
dc.citation.endPage | 427 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | ALPHA(V)BETA(3) INTEGRIN EXPRESSION | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | RGD PEPTIDES | - |
dc.subject.keywordPlus | GA-68-NOTA-RGD PET | - |
dc.subject.keywordPlus | FUSION PROTEIN | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | TRACERS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | FEASIBILITY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.